- Home
- ESE vs GH Comparison
ESE vs GH Comparison
Compare ESE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESE
- GH
- Stock Information
- Founded
- ESE 1990
- GH 2011
- Country
- ESE United States
- GH United States
- Employees
- ESE N/A
- GH N/A
- Industry
- ESE Telecommunications Equipment
- GH Medical Specialities
- Sector
- ESE Telecommunications
- GH Health Care
- Exchange
- ESE Nasdaq
- GH Nasdaq
- Market Cap
- ESE 5.0B
- GH 4.9B
- IPO Year
- ESE N/A
- GH 2018
- Fundamental
- Price
- ESE $185.17
- GH $58.88
- Analyst Decision
- ESE Strong Buy
- GH Strong Buy
- Analyst Count
- ESE 2
- GH 16
- Target Price
- ESE $187.50
- GH $57.50
- AVG Volume (30 Days)
- ESE 175.6K
- GH 3.1M
- Earning Date
- ESE 08-07-2025
- GH 07-30-2025
- Dividend Yield
- ESE 0.17%
- GH N/A
- EPS Growth
- ESE 14.55
- GH N/A
- EPS
- ESE 4.43
- GH N/A
- Revenue
- ESE $1,123,852,000.00
- GH $828,849,000.00
- Revenue This Year
- ESE $17.26
- GH $23.36
- Revenue Next Year
- ESE $14.04
- GH $21.43
- P/E Ratio
- ESE $41.88
- GH N/A
- Revenue Growth
- ESE 22.39
- GH 28.74
- 52 Week Low
- ESE $113.30
- GH $20.14
- 52 Week High
- ESE $201.72
- GH $60.68
- Technical
- Relative Strength Index (RSI)
- ESE 41.27
- GH 70.03
- Support Level
- ESE $174.92
- GH $43.66
- Resistance Level
- ESE $201.72
- GH $60.68
- Average True Range (ATR)
- ESE 5.88
- GH 2.83
- MACD
- ESE -0.81
- GH 1.72
- Stochastic Oscillator
- ESE 38.25
- GH 91.15
About ESE ESCO Technologies Inc.
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace and Defense, Utility Solutions Group (USG), and Test. The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.